Company |
Type of |
Number of |
Amount |
Investors; placement agents; details |
Date |
TOTAL: $402.74M | |||||
Ablynx NV (Ghent, Belgium) |
Exercise of warrants |
0.154S |
$1.08 |
€1.01M (US$1.08M) from the exercise of warrants, with 61.1M shares outstanding |
1/19/17 |
Amarin Corp. plc (Dublin) |
Private placement of senior notes |
N/A |
$15 |
$30M in 3.5% exchangeable senior notes due 2047 through certain investors; $15M is being used to replace debt |
1/23/17 |
Aptevo Therapeutics Inc. (Seattle) |
Investment |
N/A |
$20 |
Emergent Biosolutions Inc., of Gaithersburg, Md., paid its spin-off, Aptevo, $20M, raising its total contributions to $65M |
1/17/17 |
Biondvax Pharmaceuticals Ltd. (Ness Ziona, Israel) |
Investment |
33.8S |
$2.83 |
Angels High Tech Investments Ltd. invested NIS10.9M (US$2.83M) in exchange for 33.8M ordinary shares on Tel Aviv Stock Exchange (844,000 ADSs on Nasdaq) |
1/4/17 |
Biovie Inc. (Beverly, Mass.) |
Common stock purchase agreement |
S and W |
$0.2 |
For Aspire Capital Fund LLC to purchase up to $12M over 30 months; initial purchase was $200,000 of stock at 20 cents each, plus warrants for 500,000 shares at 50-cents-per-share exercise price within five years |
1/6/17 |
Can-Fite Biopharma Ltd. (Petach, Tikva) |
Private placement |
2.5ADS |
$5 |
$5M through 2.5M American depository shares at $2 apiece to institutional investors; Rodman & Renshaw acted as exclusive placement agent |
1/20/17 |
Cynata Therapeutics Ltd. (Melbourne, Australia) |
Private placement |
9.23S |
$4.54 |
A$6M (US$4.54M) from 9.23M shares at $0.65 each |
1/24/17 |
Cytori Therapeutics Inc. (San Diego) |
Common stock purchase agreement |
N/A |
$20 |
Lincoln Park Capital Fund LLC; up to $20M over a 30-month period |
1/3/17 |
Dimerix Ltd. (Subiaco, Western Australia) |
Private placement |
333.3S |
$1.5 |
A$2M (US$1.5M) issuing 333.3M new shares to investors at A$0.006 each |
1/26/17 |
Egalet Corp. (Wayne, Pa.) |
Debt offering |
N/A |
$40 |
$40M second tranche of the $80M secured debt financing announced Aug. 31, 2016, triggered by FDA approval of Arymo ER; Morgan Stanley & Co. LLC acted as sole placement agent |
1/20/17 |
Eiger Biopharmaceutical Inc. (Palo Alto, Calif.) |
Debt financing |
N/A |
$25 |
Oxford Finance LLC; initial $15M tranche and a second $10M tranche; interest-only for 18 months |
1/5/17 |
Helix Biopharma Corp. (Toronto) |
Private placement of units |
Units |
$1.4 |
Units at $1.20 each for C$1.82M (US$1.4M); each consists of one common share and one common share purchase warrant |
1/3/17 |
Hemostemix Inc. (Calgary, Alberta) |
Private placement of convertible debenture |
N/A |
$0.76 |
Wood Capital Ltd. acquired a C1M (US$764,000) convertible debenture that may be converted into units of Hemostemix, at a conversion price of C16 cents per unit; each unit consists of one common share and a warrant to purchase one-half share |
1/27/17 |
Inmed Pharmaceuticals Inc. (Vancouver, British Columbia) |
Private placement |
8.3U |
$1.14 |
C$1.5M (US$1.135M) from 8.3M units priced at 18 cents each in an increase of its private placement |
1/19/17 |
Ironshore Pharmaceuticals & Development Inc. (Georgetown, Grand Cayman; subsidiary of Highland Therapeutics Inc.) |
Private placement of senior notes |
N/A |
$200 |
$200M of senior secured notes due 2024; Morgan Stanley & Co. LLC acted as sole placement agent |
1/25/17 |
Kalytera Therapeutics Inc. (Vancouver, British Columbia) |
Private placement |
33.3S |
$15 |
$15M through a syndicate of agents led by Clarus Securities Inc. and including Haywood Securities Inc. and Canaccord Genuity Corp.; 33.3M shares at $0.45 each |
1/24/17 |
Knight Therapeutics Inc. (Montreal) |
Share divestment |
1.454S |
$0.31 |
C$407,851 (US$311,617) raised; Knight disposed of 1.454M shares of Pediapharm Inc., of Quebec, and for investment purposes and now holds 11.954M shares |
1/18/17 |
Matinas Biopharma Holdings Inc. (Bedminster, N.J.) |
Warrant exercise |
N/A |
$13.5 |
$13.5M from exercise of warrants; Sternaegis Ventures, through Aegis Capital Corp., acted as the warrant solicitation agent |
1/20/17 |
Oncobiologics Inc. (Cranbury, N.J.) |
Note and warrant purchase agreement |
0.379S |
$1.65 |
Closed sale of remaining $1.65 million senior secured notes and warrants to purchase 379,500 shares, bringing the total issue to $10M; Oncobiologics issued $8.35M in notes at the initial closing in December |
1/11/17 |
Oxford Biotherapeutics Ltd. (Oxford, U.K.) |
Senior secured term loan |
N/A |
$10 |
$10M senior secured term loan provided by Oxford Finance LLC; funds will be used to advance the firm's pipeline of immuno-oncology and antibody-drug conjugate programs |
1/27/17 |
Pluristem Therapeutics Inc. (Haifa, Israel) |
Bought deal financing |
14S and W for 8.4S |
$17.25 |
$17.25M through the sale of 12.2M shares at $1.225 each, with warrants to purchase up to 7.3M shares; also includes underwriter's overallotment option for 1.8M shares and warrants for 1.1M shares |
1/23/17 |
Pulmatrix Inc. (Lexington, Mass.) |
Registered direct offering |
2S |
$5 |
$5M, 2M shares at $2.50 each, from several institutional investors; Rodman & Renshaw is acting as exclusive placement agent |
1/31/17 |
Tetra Bio-Pharma Inc. (Ottawa) |
Private placement of units |
2.4U |
$0.48 |
Tetra raised $479,100 placing 2.4M units at $0.20 each; each unit consists of one common share and one non-transferable warrant, with a whole warrant entitling the holder to purchase one common share at $0.26 per share for 12 months |
1/11/17 |
Veritas Pharma Inc. (Vancouver, British Columbia) |
Private placement of units |
5U |
$1.1 |
Marapharm Ventures Inc. invested $1.1 million in Veritas through a placement of 5M units at 22 cents per unit; each consists of one common share and one share purchase warrant that entitles the company to acquire one additional share at 30 cents each for 18 months |
1/11/17 |
|
Notes This chart does not include real estate or manufacturing plant financings, or debt deals done to replace existing debt. Loan money is included in the total only when it is drawn down, if disclosed. Currency conversions are based on exchange rates at the time of the deal. The date indicated refers to the BioWorld Today issue in which the news item can be found. N/A = Not applicable; ND = Not disclosed. This chart includes only biotech companies that develop therapeutics. | |||||